Yayın:
Clinical outcomes and survival in AA amyloidosis patients

dc.contributor.buuauthorAyar, Yavuz
dc.contributor.buuauthorErsoy, Alpaslan
dc.contributor.buuauthorÖksüz, Mustafa Ferhat
dc.contributor.buuauthorOcakoğlu, Gökhan
dc.contributor.buuauthorVuruşkan, Berna Aytaç
dc.contributor.buuauthorYıldız, Abdülmecit
dc.contributor.buuauthorIşıktaş, Emel
dc.contributor.buuauthorOruç, Ayşegül
dc.contributor.buuauthorÇelikçi, Sedat
dc.contributor.buuauthorArslan, İsmail
dc.contributor.buuauthorŞahin, Ahmet Bilgehan
dc.contributor.buuauthorGüllülü, Mustafa
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPatoloji Ana Bilim Dalı
dc.contributor.departmentNefroloji Ana Bilim Dalı
dc.contributor.departmentBiyoistatistik Ana Bilim Dalı
dc.contributor.departmentRomatoloji Ana Bilim Dalı
dc.contributor.departmentDahiliye Ana Bilim Dalı
dc.contributor.orcid0000-0002-0710-0923
dc.contributor.orcid0000-0003-4607-9220
dc.contributor.orcid0000-0002-7846-0870
dc.contributor.orcid0000-0003-4607-9220
dc.contributor.researcheridAAH-5180-2021
dc.contributor.researcheridAAH-5054-2021
dc.contributor.researcheridAAH-4002-2021
dc.contributor.researcheridGSE-0029-2022
dc.contributor.researcheridO-9948-2015
dc.contributor.researcheridAAM-4927-2020
dc.contributor.researcheridAAH-9746-2021
dc.contributor.researcheridAGF-0767-2022
dc.contributor.scopusid55860143300
dc.contributor.scopusid35612977100
dc.contributor.scopusid56016440100
dc.contributor.scopusid15832295800
dc.contributor.scopusid56527372000
dc.contributor.scopusid56256977500
dc.contributor.scopusid25654785700
dc.contributor.scopusid55133912100
dc.contributor.scopusid56497114200
dc.contributor.scopusid7004617712
dc.contributor.scopusid57188809248
dc.contributor.scopusid6602684544
dc.date.accessioned2023-02-28T11:13:04Z
dc.date.available2023-02-28T11:13:04Z
dc.date.issued2016-12-29
dc.description.abstractAim: Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 +/- 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 +/- 16 months. Conclusion: Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.
dc.description.abstractResumo Objetivo: A amiloidose AA é uma complicação rara de condições inflamatórias crônicas. A maior parte dos pacientes com amiloidose AA apresenta nefropatia, que leva à insuficiência renal e à morte. Estudaram-se as características clínicas e a sobrevida em pacientes com amiloidose AA. Métodos: Analisaram-se retrospectivamente 81 pacientes (51 homens, 30 mulheres) com amiloidose AA comprovada por biópsia renal. Os pacientes foram divididos em grupos de desfecho bom e ruim de acordo com os resultados de sobrevida. Resultados: A maior parte dos pacientes (55,6%) tinha proteinúria na faixa nefrótica no momento do diagnóstico. Os distúrbios subjacentes mais frequentes foram a febre familiar do Mediterrâneo (FFM, 21,2%) e a artrite reumatoide (10,6%) no grupo de desfecho bom e a malignidade (20%) no grupo de desfecho ruim. Somente a pressão arterial diastólica no grupo de desfecho bom e o nível de fósforo no grupo de desfecho ruim foram mais elevados. Os níveis séricos de creatinina aumentaram após o tratamento em ambos os grupos, enquanto a proteinúria diminuiu no grupo de desfecho bom. O aumento na creatinina sérica e a diminuição na TFGe do grupo de desfecho ruim foram mais significativos no grupo de desfecho bom. No momento do diagnóstico, 18,5% e 27,2% de todos os pacientes tinham doença renal crônica avançada (estágios 4 e 5, respectivamente). A duração média da sobrevida renal foi de 65 ± 3,54 meses. Entre todos os pacientes, 27,1% iniciaram tratamento de diálise durante o período de seguimento e 7,4% de todos os pacientes foram submetidos a transplante renal. Níveis elevados de pressão arterial sistólica [taxas de risco (HR) 1,03, intervalo de confiança (IC) de 95%: 1 a 1,06, p = 0,036], creatinina sérica (HR 1,25, IC 95%: 1,07 a 1,46, p = 0,006) e excreção urinária de proteínas (HR 1,08, IC 95%: 1,01 a 1,16, p = 0,027) foram preditores de doença renal terminal. A mediana da sobrevida de pacientes com comprometimento de órgãos foi de 50,3 ± 16 meses. Conclusão: O presente estudo indicou que a FFM constituiu uma grande proporção de casos e crescente quantidade de pacientes com amiloidose AA idiopática. Adicionalmente, observou-se que a sobrevida do paciente não foi afetada pelas diferentes causas etiológicas na amiloidose AA.
dc.identifier.citationAyar, Y. vd. (2017). ''Clinical outcomes and survival in AA amyloidosis patients''. Revista Brasileira de Reumatologia, 57(6), 535-544.
dc.identifier.doi10.1016/j.rbre.2017.02.002
dc.identifier.endpage544
dc.identifier.issn0482-5004
dc.identifier.issue6
dc.identifier.pubmed29173691
dc.identifier.scopus2-s2.0-85034596979
dc.identifier.startpage535
dc.identifier.urihttps://doi.org/10.1016/j.rbre.2017.02.002
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2255502117300111
dc.identifier.urihttp://hdl.handle.net/11452/31251
dc.identifier.volume57
dc.identifier.wos000417146600006
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier
dc.relation.journalRevista Brasileira de Reumatologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatology
dc.subjectAA amyloidosis
dc.subjectChronic kidney disease
dc.subjectFamilial mediterranean fever
dc.subjectMortality
dc.subjectRenal survival
dc.subjectSystemic amyloidosis
dc.subjectRenal involvement
dc.subjectPrevalence
dc.subjectOrigin
dc.subject.emtreeAA amyloidosis
dc.subject.emtreeArticle
dc.subject.emtreeChronic kidney failure
dc.subject.emtreeClinical outcome
dc.subject.emtreeControlled study
dc.subject.emtreeCreatinine blood level
dc.subject.emtreeDiastolic blood pressure
dc.subject.emtreeDisease severity
dc.subject.emtreeEnd stage renal disease
dc.subject.emtreeEstimated glomerular filtration rate
dc.subject.emtreeFamilial Mediterranean fever
dc.subject.emtreeFemale
dc.subject.emtreeFollow up
dc.subject.emtreeHemodialysis
dc.subject.emtreeHuman
dc.subject.emtreeKidney transplantation
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeProteinuria
dc.subject.emtreeRetrospective study
dc.subject.emtreeRheumatoid arthritis
dc.subject.emtreeSurvival
dc.subject.emtreeUrinary excretion
dc.subject.emtreeCreatinine
dc.subject.emtreePhosphorus
dc.subject.scopusAL Amyloidosis; Cardiomyopathies; Melphalan
dc.subject.wosRheumatology
dc.titleClinical outcomes and survival in AA amyloidosis patients
dc.title.alternativeDesfechos clínicos e sobrevida em pacientes com amiloidose AA
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Nefroloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Romatoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Patoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Dahiliye Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Ayar_vd_2017.pdf
Boyut:
744.29 KB
Format:
Adobe Portable Document Format
Açıklama

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama